H.C. Wainwright analyst Robert Burns downgraded Replimune (REPL) to Neutral from Buy without a price target after the FDA issued a complete response letter for RP1 in anti-PD1 failed melanoma patients. RP1’s path to market “just got painfully longer,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Why Is Replimune Stock (REPL) Down 75% Today?
- Replimune double downgraded to Underperform from Outperform at BMO Capital
- Barclays downgrades Replimune on ‘high degree of uncertainty’
- Replimune downgraded to Equal Weight from Overweight at Barclays
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!